ArticleJournal of virology2003
Further evidence that papillomavirus capsids exist in two distinct conformations.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 120 citations in OpenAlex.
- Post-attachment neutralization of HPV16 by antibodies derived from Gardasil-vaccinated women.NPJ vaccines · 2025Article
- Variations in Genes Encoding Human Papillomavirus Binding Receptors and Susceptibility to Cervical Precancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Folliculin Prevents Lysosomal Degradation of Human Papillomavirus To Support Infectious Cell Entry.Journal of virology · 2023Article
- Human Papilloma Virus-Infected Cells.Sub-cellular biochemistry · 2023Article
- Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions.Journal of virology · 2022Article
- Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus InfectionAntimicrobial agents and chemotherapy · 2022Article
- The long and winding road: human papillomavirus entry and subcellular trafficking.Current opinion in virology · 2021Review
- Diazadispiroalkane Derivatives Are New Viral Entry Inhibitors.Antimicrobial agents and chemotherapy · 2021Article
- Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.Journal of virology · 2020Article
- Autophagy is induced in human keratinocytes during human papillomavirus 11 pseudovirion entry.Aging · 2020Article
- Article
- Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation.Scientific reports · 2018Article
- Extracellular Conformational Changes in the Capsid of Human Papillomaviruses Contribute to Asynchronous Uptake into Host Cells.Journal of virology · 2018Article
- Superinfection Exclusion between Two High-Risk Human Papillomavirus Types during a Coinfection.Journal of virology · 2018Article
- An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.Molecular cancer therapeutics · 2018Article
- High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.Viruses · 2017Article
- Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.Viruses · 2017Article
- Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions.Journal of virology · 2017Article
- The Role of DCT in HPV16 Infection of HaCaTs.PloS one · 2017Article
- The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane.Virology · 2015Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell surface heparan sulfate proteoglycans (HSPGs) serve as primary attachment receptors for human papillomaviruses (HPVs). To demonstrate that a biologically functional HPV-receptor interaction is restricted to a specific subset of HSPGs, we first explored the role of HSPG glucosaminoglycan side chain modifications. We demonstrate that HSPG O sulfation is essential for HPV binding and infection, whereas de-N-sulfated heparin interfered with VLP binding but not with HPV pseudoinfection. This points to differences in VLP-HSPG and pseudovirion-HSPG interactions. Interestingly, internalization kinetics of VLPs and pseudovirions, as measured by fluorescence-activated cell sorting analysis, also differ significantly with approximate half times of 3.5 and 7.5 h, respectively. These data suggest that differences in HSPG binding significantly influence postbinding events. We also present evidence that pseudovirions undergo a conformational change after cell attachment. A monoclonal antibody (H33.J3), which displays negligible effectiveness in preattachment neutralization assays, efficiently neutralizes cell-bound virions. However, no difference in H33.J3 binding to pseudovirions and VLPs was observed in enzyme-linked immunosorbent assay and virus capture assays. In contrast to antibody H33.B6, which displays equal efficiencies in pre- and postattachment neutralization assays, H33.J3 does not block VLP binding to heparin, demonstrating that it interferes with steps subsequent to virus binding. Our data strongly suggest that H33.J3 recognizes a conformation-dependent epitope in capsid protein L1, which undergoes a structural change after cell attachment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.